QT
BCRX icon

Quantbot Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quantbot Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
+34,296
New +$310K 0.01% 1073
2025
Q4 		– Sell
-14,844
Closed -$113K – 1715
2025
Q3 		$113K Sell
14,844
-21,308
-59% -$177K ﹤0.01% 1420
2025
Q2 		$324K Buy
+36,152
New +$337K 0.01% 1113
2024
Q4 		– Sell
-371
Closed -$2.82K – 1481
2024
Q3 		$2.82K Buy
+371
New +$2.82K ﹤0.01% 1379
2024
Q2 		– Sell
-22,300
Closed -$113K – 1442
2024
Q1 		$113K Buy
22,300
+19,900
+829% +$112K 0.01% 1141
2023
Q4 		$14.4K Sell
2,400
-61,700
-96% -$358K ﹤0.01% 1446
2023
Q3 		$454K Buy
+64,100
New +$461K 0.03% 669
2023
Q2 		– Sell
-16,500
Closed -$138K – 1579
2023
Q1 		$138K Buy
+16,500
New +$159K 0.01% 1004
2021
Q4 		– Sell
-49,800
Closed -$715K – 1504
2021
Q3 		$715K Buy
49,800
+47,700
+2,271% +$752K 0.05% 487
2021
Q2 		$33K Sell
2,100
-13,800
-87% -$187K ﹤0.01% 1142
2021
Q1 		$161K Buy
+15,900
New +$164K 0.02% 769
2020
Q4 		– Sell
-9,400
Closed -$32K – 1294
2020
Q3 		$32K Buy
+9,400
New +$40.3K ﹤0.01% 932
2015
Q3 		– Sell
-6,759
Closed -$100K – 1196
2015
Q2 		$100K Buy
+6,759
New +$76.8K 0.02% 641
2014
Q4 		– Sell
-5,527
Closed -$54K – 1128
2014
Q3 		$54K Buy
+5,527
New +$67.7K 0.01% 965
2014
Q2 		– Sell
-1,000
Closed -$10K – 1168
2014
Q1 		$10K Buy
+1,000
New +$10.7K ﹤0.01% 1021

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Quantbot Technologies's BCRX Position: Q2 2026 in Review

Quantbot Technologies opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 34,296 shares worth $343K. The stake represents 0.01% of the portfolio and ranks #1073 among its holdings. This is a return to the name: Quantbot Technologies previously reported a position in BCRX as recently as Q3 2025.

Quantbot Technologies first reported a position in BCRX in Q1 2014 and has held it in 15 quarters since. The position peaked at $715K in Q3 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Quantbot Technologies held 34,296 shares of BioCryst Pharmaceuticals worth $343K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Quantbot Technologies position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.01% of Quantbot Technologies's portfolio in Q2 2026, its #1073 holding.
  • Quantbot Technologies first reported a position in BioCryst Pharmaceuticals in Q1 2014 and has held it in 15 quarters since.
  • Quantbot Technologies's BioCryst Pharmaceuticals position peaked at $715K in Q3 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.